286 related articles for article (PubMed ID: 8309960)
1. Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphimine.
Paronis CA; Waddell AB; Holtzman SG
Pharmacol Biochem Behav; 1993 Dec; 46(4):813-7. PubMed ID: 8309960
[TBL] [Abstract][Full Text] [Related]
2. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
[TBL] [Abstract][Full Text] [Related]
3. The NMDA receptor antagonist MK-801 differentially modulates mu and kappa opioid actions in spinal cord in vitro.
Feng J; Kendig JJ
Pain; 1996 Aug; 66(2-3):343-9. PubMed ID: 8880858
[TBL] [Abstract][Full Text] [Related]
4. Opioid antagonist profile of SC nor-binaltorphimine in the formalin paw assay.
Wettstein JG; Grouhel A
Pharmacol Biochem Behav; 1996 Feb; 53(2):411-6. PubMed ID: 8808151
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay.
Broadbear JH; Negus SS; Butelman ER; de Costa BR; Woods JH
Psychopharmacology (Berl); 1994 Jul; 115(3):311-9. PubMed ID: 7871070
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of morphine-like discriminative effects by beta-funaltrexamine.
Holtzman SG
Pharmacol Biochem Behav; 1997 Aug; 57(4):771-7. PubMed ID: 9259005
[TBL] [Abstract][Full Text] [Related]
7. Suppression by nor-binaltorphimine of kappa opioid-mediated diuresis in rats.
Takemori AE; Schwartz MM; Portoghese PS
J Pharmacol Exp Ther; 1988 Dec; 247(3):971-4. PubMed ID: 2849679
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors.
Reche I; Fuentes JA; Ruiz-Gayo M
Eur J Pharmacol; 1996 Dec; 318(1):11-6. PubMed ID: 9007506
[TBL] [Abstract][Full Text] [Related]
9. Effects of opioid antagonists on unconditioned and conditioned hyperactivity to morphine.
Rauhut AS; Gehrke BJ; Phillips SB; Bardo MT
Pharmacol Biochem Behav; 2002 Oct; 73(3):611-22. PubMed ID: 12151036
[TBL] [Abstract][Full Text] [Related]
10. Long term kappa-opioid receptor blockade following nor-binaltorphimine.
Jones DN; Holtzman SG
Eur J Pharmacol; 1992 May; 215(2-3):345-8. PubMed ID: 1327807
[TBL] [Abstract][Full Text] [Related]
11. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.
Adams JU; Paronis CA; Holtzman SG
J Pharmacol Exp Ther; 1990 Dec; 255(3):1027-32. PubMed ID: 2175793
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of the morphine-induced Straub tail reaction by kappa-opioid receptor activation in mice.
Narita M; Suzuki T; Misawa M; Nagase H
Psychopharmacology (Berl); 1993; 110(1-2):254-6. PubMed ID: 7870894
[TBL] [Abstract][Full Text] [Related]
13. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice.
Takemori AE; Portoghese PS
J Pharmacol Exp Ther; 1987 Oct; 243(1):91-4. PubMed ID: 2822908
[TBL] [Abstract][Full Text] [Related]
14. General, mu and kappa opioid antagonists in the nucleus accumbens alter food intake under deprivation, glucoprivic and palatable conditions.
Bodnar RJ; Glass MJ; Ragnauth A; Cooper ML
Brain Res; 1995 Nov; 700(1-2):205-12. PubMed ID: 8624711
[TBL] [Abstract][Full Text] [Related]
15. Agonist/antagonist properties of nalbuphine, butorphanol and (-)-pentazocine in male vs. female rats.
Craft RM; McNiel DM
Pharmacol Biochem Behav; 2003 Apr; 75(1):235-45. PubMed ID: 12759132
[TBL] [Abstract][Full Text] [Related]
16. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.
Negus SS; Mello NK; Linsenmayer DC; Jones RM; Portoghese PS
Psychopharmacology (Berl); 2002 Oct; 163(3-4):412-9. PubMed ID: 12373442
[TBL] [Abstract][Full Text] [Related]
17. Further characterization of the discriminative stimulus effects of spiradoline.
Holtzman SG
Pharmacol Biochem Behav; 2000 Jul; 66(3):517-22. PubMed ID: 10899364
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats.
Steinmiller CL; Young AM
Psychopharmacology (Berl); 2008 Jan; 195(4):497-507. PubMed ID: 17882404
[TBL] [Abstract][Full Text] [Related]
19. Evidence that nor-binaltorphimine can function as an antagonist at multiple opioid receptor subtypes.
Spanagel R; Almeida OF; Shippenberg TS
Eur J Pharmacol; 1994 Oct; 264(2):157-62. PubMed ID: 7851478
[TBL] [Abstract][Full Text] [Related]
20. Differential involvement of opioid receptors in intrathecal butorphanol-induced analgesia: compared to morphine.
Wongchanapai W; Tsang BK; He Z; Ho IK
Pharmacol Biochem Behav; 1998 Mar; 59(3):723-7. PubMed ID: 9512078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
